Towards Healthcare
Cell and Gene Therapy Bioassay Services Market to Reach USD 16 Bn by 2034

Cell and Gene Therapy Bioassay Services Market Driven by Outsourcing Surge

According to forecasts, the global cell and gene therapy bioassay services market will grow from USD 5.05 billion in 2024 to USD 16 billion by 2034, with an expected CAGR of 12.24%. A rise in personalized trends is expanding the global market development. North America dominated the market due to the growing focus on the growth of specialized bioanalytical testing.

Content

  • Insight Code: 6101
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: September 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The cell and gene therapy bioassay services market is worth USD 5.67 billion in 2025, and by 2034, it is forecasted to hit USD 16 billion, registering a CAGR of 12.24% over the decade.

North America is currently leading the cell and gene therapy bioassay services market due to the rising focus on expanding demand for specialized bioanalytical testing for viral vector safety.

The cell and gene therapy bioassay services market comprises five segments by assay type, by therapy type, by application, by end user, and by region.

Some key players include Charles River Laboratories, WuXi AppTec, SGS, Eurofins Scientific, and Lonza Group.

These bioassays encompass potency testing, purity testing, cell health, and their functions in the target cells or in the modified cells.

US FDA, DBT, NIH, ClinicalTrials.gov, CMS, GOV.UK, ASGCT, BARD, NIB, NRC, USGC.
Any Questions